Silver Book Fact

A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to control different cells at specific times.

Gradinaru, Viviana, Murtaza Mogri, Kimberly R. Thompson, Jaimie M. Henderson, and Karl Deisseroth. Optical Deconstruction of Parkinsonian Neural Circuitry. Science. 2009; 324(5925): 354-9. http://www.ncbi.nlm.nih.gov/pubmed/19299587

Reference

Title
Optical Deconstruction of Parkinsonian Neural Circuitry
Publication
Science
Publication Date
2009
Authors
Gradinaru, Viviana, Murtaza Mogri, Kimberly R. Thompson, Jaimie M. Henderson, and Karl Deisseroth
Volume & Issue
Volume 324, Issue 5925
Pages
354-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.  
  • 2006 Medicines in Development for Neurologic Disorders  
  • The U.S. Food and Drug Administration has approved 5 drugs for the treatment of Alzheimer’s disease. These drugs have been found to temporarily slow the worsening of Alzheimer’s symptoms for…  
  • A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to…  
  • If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.